Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00

Hims & Hers Health (NYSE:HIMS) had its price objective raised by Bank of America from $30.00 to $32.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

HIMS has been the subject of several other research reports. UBS Group set a $23.00 target price on Hims & Hers Health in a research note on Friday, May 22nd. Truist Financial increased their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Friday, July 24th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. JPMorgan Chase & Co. reduced their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $28.79 on Tuesday. Hims & Hers Health has a one year low of $13.74 and a one year high of $65.30. The business has a fifty day moving average price of $32.07 and a 200-day moving average price of $26.08. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The firm has a market capitalization of $6.66 billion, a P/E ratio of -45.70, a PEG ratio of 57.49 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 5.89%. The company had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter last year, the firm posted $0.17 earnings per share. Hims & Hers Health’s revenue for the quarter was up 38.2% compared to the same quarter last year. As a group, equities research analysts forecast that Hims & Hers Health will post -0.05 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91. Following the completion of the sale, the chief financial officer owned 284,321 shares in the company, valued at approximately $9,675,443.63. This trade represents a 6.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells purchased 48,400 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were acquired at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the transaction, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. The trade was a 27.50% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 83,126 shares of company stock valued at $2,711,339 over the last 90 days. Insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after acquiring an additional 1,407,651 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new position in shares of Hims & Hers Health during the 4th quarter valued at $11,187,000. Cunning Capital Partners LP bought a new position in shares of Hims & Hers Health during the 4th quarter valued at $1,110,000. Norges Bank purchased a new position in Hims & Hers Health in the 4th quarter worth $62,153,000. Finally, Virtu Financial LLC purchased a new position in Hims & Hers Health in the 4th quarter worth $1,937,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers reported second-quarter revenue of $753.2 million, up 38.2% year over year and ahead of analyst expectations of $698.9 million. Subscriber growth and demand for its health and weight-management offerings remain key growth drivers. Hims & Hers Health Q2 2026 Earnings Call Summary
• Positive Sentiment: The company raised its annual revenue outlook, supporting the long-term growth case. Needham and Bank of America analysts reportedly maintained a more constructive view, suggesting the stock could appreciate as investments in new products and international expansion begin to pay off. Needham analyst outlook
• Neutral Sentiment: Hims plans to introduce certain legally available peptide products in 2026. However, analysts expect the launch to contribute little revenue this year, making it primarily a longer-term growth opportunity. As Hims prepares for peptides launch, Wall Street cautious on prospects this year
• Negative Sentiment: Quarterly EPS came in at a loss of $0.37, substantially below the expected loss of $0.05. The wider loss was linked to the shift toward branded GLP-1 obesity drugs, while gross-margin compression and negative free cash flow raised concerns that faster growth is not translating into improved earnings. Hims & Hers’ Revenue Beat Came With a Profitability Problem
• Negative Sentiment: Citigroup issued a pessimistic outlook, reflecting skepticism about near-term margins and execution. Citigroup forecast
• Negative Sentiment: Multiple law firms announced investigations into possible securities-law violations and alleged fiduciary-duty issues. The inquiries follow an FTC lawsuit concerning alleged data-sharing, billing and cancellation practices, adding legal, reputational and potential financial risks. HIMS shareholder alert

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.